Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial

被引：0
|
作者：
Strickler, J. H. [1 ]
Zemla, T. [2 ]
Ou, F-S. [2 ]
Cercek, A. [3 ]
Wu, C. [4 ]
Sanchez, F. A. [5 ]
Hubbard, J. [6 ]
Jaszewski, B. [6 ]
Bandel, L. [6 ]
Schweitzer, B. [6 ]
Niedzwiecki, D. [7 ]
Kemeny, N. [3 ]
Boland, P. M. [8 ]
Ng, K. [9 ]
Bekaii-Saab, T. [10 ]
机构：
[1] Duke Univ, Med Ctr, Div Med Oncol, Med, Durham, NC USA
[2] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
[3] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[4] Emory Univ, Hematol & Med Oncol, Atlanta, GA 30322 USA
[5] Aurora Canc Care, Advocate Aurora Hlth, Milwaukee, WI USA
[6] Mayo Clin, Med Oncol, Rochester, MN USA
[7] Duke Univ, Med Ctr, Biostat & Bioinformat, Durham, NC USA
[8] Roswell Pk Comprehens Canc Ctr, Internal Med, Buffalo, NY USA
[9] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[10] Mayo Clin, Ctr Canc, Med Oncol, Phoenix, AZ USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
527PD
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER)
    Strickler, John H.
    Cercek, Andrea
    Siena, Salvatore
    Andre, Thierry
    Ng, Kimmie
    Van Cutsem, Eric
    Wu, Christina
    Paulson, Andrew Scott
    Hubbard, Joleen M.
    Coveler, Andrew L.
    Fountzilas, Christos
    Kardosh, Adel
    Kasi, Pashtoon Murtaza
    Lenz, Heinz-Josef
    Ciombor, Kristen Keon
    Elez, Elena
    Bajor, David L.
    Nayeri, Mina
    Feng, Wentao
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.
    Siena, Salvatore
    Sartore-Bianchi, Andrea
    Lonardi, Sara
    Trusolino, Livio
    Martino, Cosimo
    Bencardino, Katia
    Leone, Francesco
    Zagonel, Vittorina
    Valtorta, Emanuele
    Torri, Valter
    Siravegna, Giulia
    Amatu, Alessio
    Bonazzina, Erica Francesca
    Rusconi, Francesca
    Ghezzi, Silvia
    Ciardiello, Fortunato
    Veronese, Silvio
    Comoglio, Paolo Maria
    Bardelli, Alberto
    Marsoni, Silvia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+metastatic colorectal cancer (mCRC) (MOUNTAINEER).
    Strickler, John H.
    Niedzwiecki, Donna
    Zemla, Tyler
    Cercek, Andrea
    Fakih, Marwan
    Ng, Kimmie
    Sanchez, Federico Augusto
    Wu, Christina Sing-Ying
    Peterson, Scott
    Bandel, Lorelei
    Grothey, Axel
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER
    Wu, C.
    Strickler, J. H.
    Cercek, A.
    Siena, S.
    Andre, T.
    Ng, K.
    Van Cutsem, E.
    Paulson, A. S.
    Hubbard, J.
    Coveler, A.
    Fountzilas, C.
    Kardosh, A.
    Kasi, P. M.
    Lenz, H. J.
    Ciombor, K. K.
    Fernandez, M. E. Elez
    Hsu, L. I.
    Stecher, M.
    Zhao, K.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S700 - S701
  • [5] Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC
    Strickler, J.
    Cercek, A.
    Siena, S.
    Andre, T.
    Ng, K.
    Van Cutsem, E.
    Wu, C.
    Paulson, A.
    Hubbard, J.
    Coveler, A.
    Fountzilas, C.
    Kardosh, A.
    Kasi, P.
    Lenz, H.
    Ciombor, K.
    Elez, E.
    Bajor, D.
    Stecher, M.
    Feng, W.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S375 - S376
  • [6] Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC
    Strickler, J. H.
    Cercek, A.
    Siena, S.
    Andre, T.
    Ng, K.
    Van Cutsem, E.
    Wu, C.
    Paulson, A. S.
    Hubbard, J.
    Coveler, A.
    Fountzilas, C.
    Kardosh, A.
    Kasi, P. M.
    Lenz, H. J.
    Ciombor, K. K.
    Fernandez, M. E. Elez
    Bajor, D. L.
    Stecher, M.
    Feng, W.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1394 - S1394
  • [7] Final Results of the HERACLES trial in HER2 amplified colorectal cancer
    Siena, S.
    Sartore-Bianchi, A.
    Trusolino, L.
    Martino, C.
    Bencardino, K.
    Lonardi, S.
    Zagonel, V.
    Leone, F.
    Martinelli, E.
    Ciardiello, F.
    Racca, P.
    Amatu, A.
    Palmeri, L.
    Valtorta, E.
    Cassingena, A.
    Vanzulli, A.
    Regge, D.
    Veronese, S.
    Bardelli, A.
    Marsoni, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
    Strickler, J.
    Ng, K.
    Cercek, A.
    Fountzilas, C.
    Sanchez, F.
    Hubbard, J.
    Wu, C.
    Stecher, M.
    Walker, L. N.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S460 - S461
  • [9] MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (trial in progress)
    Andre, T.
    Bekaii-Saab, T.
    Tabernero, J.
    Siena, S.
    Yoshino, T.
    Norwood, K. G.
    Adelberg, D. E.
    Ward, J.
    Yang, S.
    Strickler, J. H.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S734 - S735
  • [10] Pertuzumab plus trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway
    Hurwitz, Herbert
    Raghav, Kanwal Pratap Singh
    Burris, Howard A.
    Kurzrock, Razelle
    Sweeney, Christopher
    Meric-Bernstam, Funda
    Vanderwalde, Ari M.
    Spigel, David R.
    Bose, Ron
    Fakih, Marwan
    Swanton, Charles
    Guo, Shuangli
    Bernaards, Coen
    Beattie, Mary Stanley
    Sommer, Nicolas
    Hainsworth, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345